Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Amryt Pharma

Evaluate

April 05, 2023

Biopharma stocks go back to bleak

Hopes for a better 2023 look optimistic as markets take another turn for the worse.

Thumbnail
January 09, 2023

JP Morgan 2023 – day one sees buyers make the most of straitened times

Takeouts of Cincor, Albireo and Amryt emerge with contingent payment terms, as biopharma buyers flex their muscles.

Article image
Vantage logo
November 04, 2022

Abeona takes on Amryt – and more importantly, Krystal

Three new epidermolysis bullosa therapies are approaching the US, and expectations vary wildly.

Article image
Vantage logo
March 02, 2022

US FDA approval tracker: February 2022

Article image
Vantage logo
January 26, 2022

Go or no go? Pdufa resolutions eyed for J&J and Amryt

February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.

Article image
Vantage logo
December 01, 2021

US FDA approval tracker: November 2021

Article image
Vantage logo
November 29, 2021

Krystal shines in epidermolysis bullosa

Look out Amryt: Krystal’s topical gene therapy is gaining ground.

Article image
Vantage logo
October 29, 2021

Go or go go? J&J’s cell therapy heads to the FDA

November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.

Article image
Vantage logo
September 07, 2021

As Forte fails, who might yet improve the image of reverse mergers?

Among developers that arrived on the market via reverse mergers, big success stories are hard to find.

Article image
Vantage logo
April 28, 2021

Epidermolysis bullosa gene therapies wait in the wings

Amryt marches ahead, but gene therapies from Krystal, Abeona and Castle Creek are heading towards data readouts.

Article image
Vantage logo
October 29, 2020

Amryt data strengthen the case for approval

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up